Sofituzumab vedotin

Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer[1].

Product Specifications

CAS Number

[1418200-58-4]

Product Name Alternative

DMUC5754A

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs)

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sofituzumab-vedotin.html

Purity

98.72

Solubility

H2O

Smiles

[Sofituzumabvedotin]

Molecular Weight

144000 (average)

References & Citations

[1]Manzano A, et al. Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer. Cancers (Basel) . 2020 Aug 9;12 (8) :2223.|[2]Liu JF, et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 Nov;27 (11) :2124-2130.|[3]Chen Y, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007 May 15;67 (10) :4924-32.